Trial Profile
Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms RESPONDER
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Oct 2021 Results (n=56) assessing to identify early changes in T-cell subsets that underlie anti-PD1 efficacy in metastatic urothelial cancer patients, published in the Clinical Cancer Research.
- 19 Aug 2021 Planned End Date changed from 21 Aug 2020 to 19 Aug 2023.